meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - 2nd line (L2)
3
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
avelumab plus pegylated liposomal doxorubicin
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs anthracyclines
vs doxorubicin
vs pegylated liposomal doxorubicin
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
avelumab plus pegylated liposomal doxorubicin
title
pegylated liposomal doxorubicin
title
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 NCT02580058 metastatic/advanced OC (mOC) - 2nd line (L2) 188/190
Pathology:
metastatic/advanced OC (mOC) - 2nd line (L2);
metastatic/advanced OC (mOC) - 2nd line (L2)
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021
avelumab plus pegylated liposomal doxorubicin
1
T1
pegylated liposomal doxorubicin
0
T0